154 related articles for article (PubMed ID: 38302801)
21. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen.
Freedland SJ; Terris MK; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Aronson WJ;
J Urol; 2004 Jun; 171(6 Pt 1):2215-20. PubMed ID: 15126788
[TBL] [Abstract][Full Text] [Related]
22. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations.
Ślusarczyk A; Baboudjian M; Zapała P; Yanagisawa T; Miszczyk M; Chlosta M; Krumpoeck P; Moschini M; Gandaglia G; Ploussard G; Rivas JG; Życzkowski M; Karakiewicz PI; Radziszewski P; Leapman MS; Shariat SF; Rajwa P
Prostate; 2023 Nov; 83(15):1504-1515. PubMed ID: 37545342
[TBL] [Abstract][Full Text] [Related]
23. Transurethral resection of the prostate is an independent risk factor for biochemical recurrence after radical prostatectomy for prostate cancer.
Jin K; Qiu S; Liao XY; Zheng XN; Tu X; Tang LS; Yang L; Wei Q
Asian J Androl; 2020; 22(2):217-221. PubMed ID: 31210148
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
25. Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
Nagao K; Matsuyama H; Matsumoto H; Nasu T; Yamamoto M; Kamiryo Y; Baba Y; Suga A; Tei Y; Yoshihiro S; Aoki A; Shimabukuro T; Joko K; Sakano S; Takai K; Yamaguchi S; Akao J; Kitahara S;
Int J Clin Oncol; 2018 Aug; 23(4):757-764. PubMed ID: 29589154
[TBL] [Abstract][Full Text] [Related]
26. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
27. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening.
D'Amico AV; Whittington R; Malkowicz SB; Renshaw AA; Tomaszewski JE; Bentley C; Schultz D; Rocha S; Wein A; Richie JP
Urology; 2001 Sep; 58(3):406-10. PubMed ID: 11549489
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
Ravi P; Kwak L; Xie W; Kelleher K; Acosta AM; McKay RR; Kibel AS; Taplin ME
J Urol; 2022 Oct; 208(4):838-845. PubMed ID: 36082554
[TBL] [Abstract][Full Text] [Related]
29. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
30. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
31. LONG-TERM RADICAL PROSTATECTOMY ONCOLOGIC OUTCOMES IN PATIENTS WITH CLINICALLY LOCALLY ADVANCED PROSTATE CANCER: A SINGLE-CENTER STUDY.
Grygorenko V; Afanasiev Y; Danylets R; Vikarchuk M; Kosyuchno M; Pasichnyk S
Exp Oncol; 2022 May; 44(1):67-74. PubMed ID: 35548960
[TBL] [Abstract][Full Text] [Related]
32. The relationship between age at time of surgery and risk of biochemical failure after radical prostatectomy.
Barlow LJ; Badalato GM; Bashir T; Benson MC; McKiernan JM
BJU Int; 2010 Jun; 105(12):1646-9. PubMed ID: 19863523
[TBL] [Abstract][Full Text] [Related]
33. The prognostic nomogram for PSA-incongruent low-risk prostate cancer treated by radical prostatectomy.
Wang Y; Zhu Y; Fan L; Liu J; Pan J; Xue W
Int Urol Nephrol; 2023 Jun; 55(6):1447-1452. PubMed ID: 37017821
[TBL] [Abstract][Full Text] [Related]
34. Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort.
Lonergan PE; Cowan JE; Washington SL; Greenberg SA; Nguyen HG; Carroll PR
Prostate; 2021 Sep; 81(13):1009-1017. PubMed ID: 34288004
[TBL] [Abstract][Full Text] [Related]
35. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
[TBL] [Abstract][Full Text] [Related]
36. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies.
Krasnow RE; Rodríguez D; Nagle RT; Mossanen M; Kibel AS; Chang SL
Urol Oncol; 2018 Nov; 36(11):500.e11-500.e19. PubMed ID: 30249519
[TBL] [Abstract][Full Text] [Related]
37. Gleason Score ≤ 6 Prostate Cancer at Radical Prostatectomy: Does a High-Risk Setting Truly Exist? A Recursive Partitioning Analysis.
Watkins JM; Mitchell DL; Russo JK; Mott SL; Tracy CR; Smith MC; Buatti JM
Clin Genitourin Cancer; 2017 Apr; 15(2):242-247. PubMed ID: 27338519
[TBL] [Abstract][Full Text] [Related]
38. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Blank K; Broderick GA; Tomaszewski JE; Renshaw AA; Kaplan I; Beard CJ; Wein A
JAMA; 1998 Sep; 280(11):969-74. PubMed ID: 9749478
[TBL] [Abstract][Full Text] [Related]
39. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
[TBL] [Abstract][Full Text] [Related]
40. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
